Critical Contrast: Theravance Biopharma (TBPH) vs. The Competition

Theravance Biopharma (NASDAQ:TBPH) is one of 897 publicly-traded companies in the “Pharmaceuticals” industry, but how does it compare to its competitors? We will compare Theravance Biopharma to related businesses based on the strength of its dividends, earnings, risk, analyst recommendations, valuation, institutional ownership and profitability.

Risk & Volatility

Theravance Biopharma has a beta of 0.25, meaning that its share price is 75% less volatile than the S&P 500. Comparatively, Theravance Biopharma’s competitors have a beta of -4.29, meaning that their average share price is 529% less volatile than the S&P 500.

Valuation & Earnings

This table compares Theravance Biopharma and its competitors revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Theravance Biopharma	$104.31 million	$105.89 million	16.86
Theravance Biopharma Competitors	$3.54 billion	$3.16 billion	545.52

Theravance Biopharma’s competitors have higher revenue and earnings than Theravance Biopharma. Theravance Biopharma is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Insider & Institutional Ownership

99.1% of Theravance Biopharma shares are held by institutional investors. Comparatively, 32.4% of shares of all “Pharmaceuticals” companies are held by institutional investors. 7.6% of Theravance Biopharma shares are held by company insiders. Comparatively, 14.2% of shares of all “Pharmaceuticals” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Profitability

This table compares Theravance Biopharma and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Theravance Biopharma	51.58%	-0.77%	-0.46%
Theravance Biopharma Competitors	-2,380.91%	-221.73%	-15.99%

Analyst Recommendations

This is a breakdown of recent ratings and price targets for Theravance Biopharma and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Theravance Biopharma	0	7	0	0	2.00
Theravance Biopharma Competitors	7752	13841	25687	1031	2.41

Theravance Biopharma presently has a consensus target price of $19.00, suggesting a potential upside of 11.57%. As a group, “Pharmaceuticals” companies have a potential upside of 23.94%. Given Theravance Biopharma’s competitors stronger consensus rating and higher probable upside, analysts plainly believe Theravance Biopharma has less favorable growth aspects than its competitors.

Summary

Theravance Biopharma competitors beat Theravance Biopharma on 8 of the 13 factors compared.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs.
Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY.
For more information, please visit www.theravance.com.